Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials

Fig. 3

Mean percent change (± SD) from baseline in bone turnover markers (Urine NTX (a), Urine CTX (b) and Serum BAP (c)) in receiving risedronate. Patients were stratified into three cohorts by eGFR in baseline, and the mean percent change in bone turnover markers in each cohort was shown. *p < 0.001, significantly different from baseline

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us